Beta bionics, inc.BBNX.US Overview
BBNX Overall Performance
BBNX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
BBNX Key Information
BBNX Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
BBNX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
BBNX Profile
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Price of BBNX
BBNX FAQ
When is BBNX's latest earnings report released?
The most recent financial report for Beta bionics, inc. (BBNX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BBNX's short-term business performance and financial health. For the latest updates on BBNX's earnings releases, visit this page regularly.
What is the operating profit of BBNX?
According to the latest financial report, Beta bionics, inc. (BBNX) reported an Operating Profit of -17.04M with an Operating Margin of -62.54% this period, representing a decline of 55.26% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is BBNX's revenue growth?
In the latest financial report, Beta bionics, inc. (BBNX) announced revenue of 27.25M, with a Year-Over-Year growth rate of 63.14%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does BBNX have?
As of the end of the reporting period, Beta bionics, inc. (BBNX) had total debt of 7.69M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does BBNX have?
At the end of the period, Beta bionics, inc. (BBNX) held Total Cash and Cash Equivalents of 38.59M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does BBNX go with three margins increasing?
In the latest report, Beta bionics, inc. (BBNX) did not achieve the “three margins increasing” benchmark, with a gross margin of 55.5%%, operating margin of -62.54%%, and net margin of -52.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BBNX's profit trajectory and future growth potential.
Is BBNX's EPS continuing to grow?
According to the past four quarterly reports, Beta bionics, inc. (BBNX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.33. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of BBNX?
Beta bionics, inc. (BBNX)'s Free Cash Flow (FCF) for the period is -10.01M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 13.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of BBNX?
The latest valuation data shows Beta bionics, inc. (BBNX) has a Price-To-Earnings (PE) ratio of -13.73 and a Price/Earnings-To-Growth (PEG) ratio of 0.99. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.